|
|
Article: Agensys Brings In $41.3M For Work On Anticancer Antibodies.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Agensys Inc. raised $41.3 million in a Series D round of financing to fund development of the 12 antibody products in its pipeline.
The Santa Monica, Calif.-based firm said its therapeutic antibodies, many of which are fully human, are being generated to a portfolio of cancer targets that encompass 14 types of solid tumors. Among its significant collaborations are deals with Merck and Co. Inc., Seattle Genetics Inc., Genentech Inc., Amgen Inc. and Sanofi Pasteur.
The company's lead product is AGS-PSCA, a monoclonal antibody targeting prostate stem cell antigen that was the subject of a potential $170 million deal from 2005 with Merck, of Whitehouse ...